Ildong Pharmaceutical announced on the 23rd that it has been approved by the MFDS to change the clinical trial plan of Shionogi's oral COVID-19 treatment candidate "S-217622" under development in Korea.
​
Earlier, Ildong Pharmaceutical applied to change its clinical plan in the direction of confirming the results of each phase by modifying the existing plan to conduct phase 2b/3 clinical trials of S-217622 at once and dividing it into phase 2b and phase 3. Ildong Pharmaceutical plans to separate and check the validity and safety of Phase 2b and Phase 3 while continuing the existing clinical trials that have been conducted in Korea since the beginning of this year.​
​​